Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Clinical Efficacy and Safety of Bempedoic Acid in High Cardiovascular Risk Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Ist Teil von
Current problems in cardiology, 2023-12, Vol.48 (12), p.102003-102003, Article 102003
Ort / Verlag
Netherlands: Elsevier Inc
Erscheinungsjahr
2023
Quelle
Elsevier ScienceDirect Journals
Beschreibungen/Notizen
Bempedoic Acid (BA) is the new addition to lipid-lowering medications. This systematic review and meta-analysis of randomized controlled trials (RCTs) assess the clinical efficacy and safety of BA in high cardiovascular (CV) risk patients along with its effects on low-density lipoprotein cholesterol (LDL-C) and total cholesterol. PubMed, Google Scholar, Cochrane Central Register of Controlled Trials, Embase, and ClinicalTrials.gov were searched for RCTs comparing BA with placebo, reporting CV outcomes. Seven RCTs with a total of 17,816 patients were selected for the analysis. Results showed that BA significantly reduced the risk of MACE (RR 0.87, 95%CI 0.80 to 0.94; p=0.007), non-fatal myocardial infarction (RR 0.73; 95%CI 0.62 to 0.85; P<0.0001), hospitalization for unstable angina (RR 0.69; 95%CI 0.54 to 0.88; p=0.003), coronary and non-coronary revascularization (RR 0.82; 95%CI 0.73 to 0.92; p=0.0007) and (RR 0.41; 95%CI 0.18 to 0.96;p=0.04) respectively. However, BA increased the risk of gout (RR 1.55; 95%CI 1.26 to 1.90; p<0.0001), hyperuricemia (RR 1.94; 95%CI 1.73 to 2.18; p<0.00001), and worsening renal function (RR 1.34; 95%CI 1.21 to 1.48; p<0.00001). BA also reduced LDL-C (MD -22.38%; 95%CI -25.94 to - 18.82; p <0.00001) and total cholesterol (MD -13.86%; 95%CI -15.82 to -11.91; p<0.0000) compared with placebo. Bempedoic Acid is an addition to the arsenal of lipid-lowering drugs used in patients that are statin intolerant or need additional lipid-lowering therapy.